首页> 外文OA文献 >Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

【2h】

Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

机译：靶介导的消除对Evolocumab的剂量和方案的影响，一种针对Proprotein转化酶枯草杆菌蛋白酶/ kexin型9（PCSK9）的人单克隆抗体

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
John P. Gibbs; Sameer Doshi; Mita Kuchimanchi; Anita Grover; Maurice G. Emery; Michael G. Dodds; Megan A. Gibbs; Ransi Somaratne; Scott M. Wasserman; Dirk Blom;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) [J] . Gibbs John P., Doshi Sameer, Kuchimanchi Mita, The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology . 2017,第5期

机译：靶介导的消除对Evolocumab的剂量和方案的影响，一种针对Proprotein转化酶枯草杆菌蛋白酶/ kexin型9（PCSK9）的人单克隆抗体
2. Effect of proprotein convertase subtilisin/kexin type 9 ( PCSK9 PCSK9 ) monoclonal antibodies on new‐onset diabetes mellitus and glucose metabolism: A A systematic review and meta‐analysis [J] . Cao Ye‐Xuan, Liu Hui‐Hui, Dong Qiu‐Ting, Diabetes, obesity & metabolism . 2018,第6期

机译：Proprotein转化酶枯草杆菌素/ kexin型9（PCSK9 PCSK9）单克隆抗体对新发起糖尿病和葡萄糖代谢的影响：A系统综述和荟萃分析
3. Residual Risk After Treatment of Patients With Atherosclerotic Cardiovascular Disease With Proprotein Convertase Subtilisin-Kexin Type 9 Monoclonal Antibody Therapy (from the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Trial) [J] . Wong Nathan D. The American Journal of Cardiology . 2017,第7期

机译：用Proprotein转化酶枯草杆菌蛋白酶-kexin患者治疗动脉粥样硬化性心血管疾病患者后的残留风险（从升高风险试验中的受试者中的PCSK9抑制的进一步心血管结果研究）
4. Towards Investigating the Role of Proprotein Convertase Subtilisin/Kexin Family (PCSK/7/9) in Cancer by Using Bioinformatics Motif Detection Technique [C] . Umar Draz, Sana Yasin, Shafiq Hussain, International Bhurban Conference on Applied Sciences and Technologies . 2021

机译：通过使用生物信息学主题检测技术来研究Proprotein转化酶枯草杆菌素/ kexin家族（PCSK / 7/9）的作用
5. Evaluation of the Interaction Between Proprotein Convertase Subtilisin/Kexin Type 9 and Sterol Carrier Protein-2 [D] . Ahranjani, Reza. 2017

机译：评价前蛋白转化酶枯草杆菌蛋白酶/ Kexin 9型与甾醇载体蛋白2的相互作用。
6. Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) [O] . John P. Gibbs, Sameer Doshi, Mita Kuchimanchi, -1

机译：目标消除对Evolocumab的剂量和方案的影响Evolocumab是抗9型前蛋白转化酶枯草杆菌蛋白酶/ Kexin的人类单克隆抗体（PCSK9）
7. SAFETY AND EFFICACY OF LY3015014, A NEW MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) WITH AN INHERENTLY LONGER DURATION OF ACTION, IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: A RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING, PHASE 2 STUDY [O] . Kastelein John, Nissen Steven, Rader Daniel, 2015

机译：LY3015014的安全性和有效性，它是一种具有蛋白原价更长的作用持续时间的蛋白转化蛋白水解酶/ KEXIN 9型（PCSK9）单克隆抗体，在原发性高胆固醇血症患者中进行了2例随机对照研究
8. Development of Methods for Carrier-Mediated Targeted Delivery of AntiviralCompounds Using Monoclonal Antibodies (Final Report) [R] . Dawson, M. I., Sidwell, W., Barnett, B. 1990

机译：使用单克隆抗体开发载体介导的抗病毒化合物靶向递送方法（最终报告）

Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

著录项

引文网络

相似文献

相关主题

期刊订阅